Recorded Presentation from the NCCN 2015 Congress Webinar Series: GU Cancers - Metastatic RCC: Selecting Optimal First-Line and Subsequent-Lines of Therapy

This educational initiative addresses healthcare professionals’ need to be educated on practice-changing developments in the management of advanced genitourinary cancers that have taken center stage in recent years. The expansion of treatment options has improved patient care but has presented numerous clinical challenges. 

For example, despite significant improvements in responses and survival with the use of TKIs and mTOR inhibitors as first-line therapy in patients with RCC, progression is universal in these patients. This underscores the need to understand optimal second-line therapy, optimal sequence of therapies, and novel treatment approaches such as immunotherapeutics that are currently in various phases of clinical development.

Target Audience

This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, urologists, and other healthcare professionals who manage patients with GU cancers.

Learning Objectives

Following this activity, participants should be able to:

  • Explain the molecular biology of renal cell carcinoma
  • Categorize the risks and benefits of the current therapeutic options available for patients with newly diagnosed advanced renal cell carcinoma
  • Select optimal subsequent lines of treatment to improve outcomes of patients with advanced RCC
  • Discuss the scientific rationale used in developing current and emerging therapeutics for advanced RCC
Additional information
Supporters: 

This activity is supported by an independent educational grant from Astellas and Medivation, Inc.

Supported by educational grants from Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, and Prometheus Laboratories Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.95 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/23/2015
Course expires: 
12/23/2016
Cost:
$0.00

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center

M. Dror Michaelson, MD, PhD
Massachusetts General Hospital Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have disclosed the following relevant financial relationships:

Eric Jonasch, MD
Bristol-Myers Squibb Company Consulting Fees, Honoraria
Exelixis Inc.: Consulting Fees, Honoraria; Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Grant/Research Support
Onyx Pharmaceuticals, Inc.: Grant/Research Support
Pfizer Inc.: Consulting Fees, Honoraria; Grant/Research Support
Roche Laboratories, Inc.: Consulting Fees, Honoraria

M. Dror Michaelson, MD, PhD
Argos Therapeutics, Inc: Grant/Research Support
Eisai Inc.: Grant/Research Support
Medivation, Inc.: Scientific Advisor
Millennium Pharmaceuticals, Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Scientific Advisor

NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Mary Dwyer, MS; Rashmi Kumar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date: December 23, 2015
Expiration date: December 23, 2016

Nurses

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.95 contact hour. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Release date: December 23, 2015
Expiration date: December 23, 2016

Pharmacists

false

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge 

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-15-154-H01-P

Release date: December 23, 2015
Expiration date: December 23, 2016

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.95 ANCC contact hours
  • 1.00 Participation

Accreditation Period

Course opens: 
12/23/2015
Course expires: 
12/23/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing